既往甲状腺癌与非甲状腺癌病史未显著改变未分化甲状腺癌患者的总生存期
该回顾性队列研究纳入2000至2019年在MD安德森癌症中心治疗的451例未分化甲状腺癌(ATC)患者,分析既往甲状腺癌及非甲状腺癌病史对总生存期(OS)的影响。多因素分析校正年龄和总体分期后,既往分化型甲状腺癌、同时存在的分化型甲状腺癌及既往非甲状腺癌均对OS无显著影响。作者认为应修订ATC患者入组临床试验的资格标准。
要点
- 451例ATC患者中,14%(n=62)有临床记录的分化型甲状腺癌病史,病理同时发现分化型甲状腺癌者占52%(n=234)。
- 23%(n=102)有非甲状腺癌病史,最常见为非黑色素瘤皮肤癌(28.4%)、前列腺癌(19.6%)和乳腺癌(16.7%)。
- 多因素分析校正年龄和总体分期后,既往分化型甲状腺癌、同时分化型甲状腺癌及既往非甲状腺癌均对OS无显著影响。
核心结论
- 既往恶性肿瘤病史对未分化甲状腺癌患者的总生存期无显著影响。
- 作者认为有必要修订未分化甲状腺癌患者入组临床试验的资格标准。
研究设计与样本
- 回顾性队列研究,纳入2000至2019年在MD安德森癌症中心治疗的451例未分化甲状腺癌患者,通过病历回顾获取临床和病理信息。
- 采用Kaplan-Meier法和多因素Cox比例风险模型进行生存分析。
主要发现
- 14%(n=62)有临床记录的分化型甲状腺癌病史,其中最常见为甲状腺乳头状癌(81%,n=50);从既往分化型甲状腺癌诊断到未分化甲状腺癌诊断的中位时间为3.5年(范围:6个月至35年)。
- 病理同时发现分化型甲状腺癌者比例更高(52%,n=234)。
- 23%(n=102)有非甲状腺癌病史,其中19%(n=87)有一种、2%(n=10)有两种、1%(n=5)有三种既往癌症;从既往非甲状腺癌诊断到未分化甲状腺癌诊断的中位时间为8年(范围:3个月至53年)。
- 最常见的既往非甲状腺癌为非黑色素瘤皮肤癌(28.4%)、前列腺癌(19.6%)和乳腺癌(16.7%)。
- 在具有肿瘤突变信息的183例患者亚组分析中,检测到的肿瘤驱动突变(BRAF、RAS、TP53)频率在有和无非甲状腺癌病史的未分化甲状腺癌患者之间无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: A history of thyroid and nonthyroid malignancies has traditionally been an exclusion criterion in patients with anaplastic thyroid cancer (ATC) seeking to enroll in clinical trials. In this study, we examined the impact of prior malignancies on overall survival (OS) in patients diagnosed with ATC. Methods: In our retrospective cohort study, we identified 451 patients with ATC treated at MD Anderson between 2000 and 2019. Clinical and pathological information was obtained through chart review. Survival analyses were conducted using the Kaplan-Meier method and multivariable Cox proportional hazard models. Results: A history of clinically documented differentiated thyroid cancer (DTC) was reported in 14% of patients with ATC (n = 62), most commonly papillary thyroid cancer (81%, n = 50). The median time from diagnosis of prior DTC to ATC diagnosis was 3.5 years (range: 6 months to 35 years). Concomitant DTC was found on pathology in a higher proportion of patients (52%, n = 234). A history of nonthyroid cancer was reported in 23% of patients (n = 102), where 19% (n = 87) had one, 2% (n = 10) had two, and 1% (n = 5) had three prior cancers. The median time from diagnosis of prior nonthyroid cancer to ATC diagnosis was 8 years (range: 3 months to 53 years). The most common prior nonthyroid cancers were nonmelanoma skin (28.4%), prostate (19.6%), and breast cancers (16.7%). In a subgroup analysis performed in patients with available tumor mutation information (n = 183), the frequency of detected tumor driver mutations (BRAF, RAS, TP53) was not significantly different between patients with ATC with and without a history of nonthyroid cancer. On multivariate analysis after adjusting for age and overall stage, prior DTC, concomitant DTC, and prior nonthyroid cancers, all had no significant impact on OS. Conclusions: The presence of prior malignancy does not significantly impact OS in patients with ATC. Revision of eligibility criteria for enrollment of patients with ATC into clinical trials is warranted.
引用
- Chen YH, Cabanillas M, Sperling J, et al. Prior Thyroid and Nonthyroid Cancer History Do Not Significantly Alter Overall Survival in Patients Diagnosed with Anaplastic Thyroid Cancer. Thyroid. 2023. PMID: 36511380. doi:10.1089/thy.2022.0350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。